ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ASMB Assembly Biosciences Inc

15.39
0.26 (1.72%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 18,464
Bid Price 14.26
Ask Price 15.94
News -
Day High 15.70

Low
7.692

52 Week Range

High
20.04

Day Low 14.8082
Company Name Stock Ticker Symbol Market Type
Assembly Biosciences Inc ASMB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 1.72% 15.39 20:00:00
Open Price Low Price High Price Close Price Prev Close
15.07 14.8082 15.70 15.39 15.13
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
226 18,464 $ 15.19 $ 280,557 - 7.692 - 20.04
Last Trade Time Type Quantity Stock Price Currency
16:00:00 279 $ 15.39 USD

Assembly Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
82.24M 5.48M - 7.16M -61.23M -11.17 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Assembly Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ASMB Message Board. Create One! See More Posts on ASMB Message Board See More Message Board Posts

Historical ASMB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.4216.2714.2815.1516,724-0.03-0.19%
1 Month14.8916.4514.2515.0814,6650.503.36%
3 Months12.3716.4512.0013.9018,4073.0224.41%
6 Months9.2416.458.818810.99148,3456.1566.56%
1 Year12.958820.047.69212.89588,5842.4318.76%
3 Years52.585252.58527.69223.94544,727-37.20-70.73%
5 Years182.76348.007.69264.35576,645-167.37-91.58%

Assembly Biosciences Description

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Your Recent History

Delayed Upgrade Clock